These highlights do not include all the information needed to use GLUCAGON FOR INJECTION safely and effectively. See full prescribing information for GLUCAGON FOR INJECTION.
GLUCAGON for injection, for intravenous or intramuscular use
Initial U.S. Approval: 1998
INDICATIONS AND USAGE
Glucagon for Injection is a gastrointestinal motility inhibitor indicated for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal (GI) tract (1)
Limitations of Use:
Glucagon for Injection is not indicated for the emergency treatment of hypoglycemia (1)
DOSAGE AND ADMINISTRATION
Reconstitute lyophilized powder with Sterile Water for Injection before use (2.2, 2.3)
Determine dose based on diagnostic procedure, route of administration and procedure duration (2.1):
To inhibit stomach and small bowel motility the dose is 0.2 mg to 0.5 mg given intravenously or 1 mg given intramuscularly
To inhibit colon motility the dose is 0.5 mg to 0.75 mg given intravenously or 1 mg to 2 mg given intramuscularly
DOSAGE FORMS AND STRENGTHS
For Injection: 1 mg lyophilized powder in single dose vial for reconstitution (3)
CONTRAINDICATIONS
Pheochromocytoma (4, 5.1)
Insulinoma (4, 5.2)
Glucagonoma (4, 5.2)
WARNINGS AND PRECAUTIONS
Hyperglycemia in patients with diabetes: Monitor blood glucose and treat with insulin if indicated (5.3)
Increased blood pressure and heart rate in patients with cardiac disease: Monitor patients with known cardiac disease (5.4)
Allergic reactions including anaphylactic shock with breathing difficulties, and hypotension, generalized rash: Discontinue and treat as indicated (5.5)
ADVERSE REACTIONS
Adverse reactions seen with glucagon are transient changes in blood pressure, increase in heart rate, hypersensitivity reactions, nausea and vomiting, and hypoglycemia (6)
To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS
Beta-blockers: May cause a greater increase in both heart rate and blood pressure (7)
Insulin: Reacts antagonistically towards glucagon; monitor glucose (7)
Indomethacin: May produce hypoglycemia; monitor glucose (7)
Anticholinergic Drugs: Concomitant use not recommended due to increased gastrointestinal adverse reactions (7)
Warfarin: May increase anticoagulant effect of warfarin; may require an adjustment in warfarin dosage (7)
See 17 for PATIENT COUNSELING INFORMATION.
Revised: 2/2022
